Effect of delays on prognosis in patients with non-small cell lung cancer

Myrdal G; Lambe M; Hillerdal G; Lamberg K; Agustsson Th; St''hle E
January 2004
Thorax;Jan2004, Vol. 59 Issue 1, p45
Academic Journal
BACKGROUND: The effect of delay on survival in lung cancer remains uncertain. It is suggested that prompt management of non-small cell lung cancer (NSCLC) can influence prognosis. This study was undertaken to examine the relation between delay and prognosis in patients with NSCLC and to investigate the delay time from first symptom and from first hospital visit to start of treatment. METHODS: Two types of delay (symptom to treatment delay and hospital delay) were investigated in 466 patients treated for NSCLC at two institutions in central Sweden. Delays in relation to clinical characteristics were compared and the effects of delay times and other relevant factors on survival were assessed in multivariate analyses. RESULTS: Thirty five per cent of patients received treatment within 4 weeks of the first hospital visit and 52% within 6 weeks. Median symptom to treatment delay was 4.6 months and median hospital delay 1.6 months. Older age, advanced tumour stage, and non-surgical treatment were independently related to poor survival. Both prolonged hospital delay and symptom to treatment delay provided additional information when considered separately. In a final multivariate model only increased symptom to treatment delay gave significant information of a better prognosis. There was an association between a short delay and a poor prognosis which was most pronounced in patients with advanced disease. CONCLUSION: When considering the whole study population and all stages of tumour together, shorter delay was associated with a poorer prognosis. This is likely to reflect the fact that patients with severe signs and symptoms receive prompt treatment. These findings indicate that the waiting time for treatment in patients with NSCLC is longer than recommended.


Related Articles

  • Lymphatic invasion of micropapillary cancer cells is associated with a poor prognosis of pathological stage IA lung adenocarcinomas. HIROSHI HIRANO; HAJIME MAEDA; YUKIYASU TAKEUCHI; YOSHIYUKI SUSAKI; RYOZI KOBAYASHI; AKIO HAYASHI; NAOKO OSE; TOSHIHIKO YAMAGUCHI; SOICHIRO YOKOTA; MASAHIDE MORI // Oncology Letters;2014, Vol. 8 Issue 3, p1107 

    The cancer cells of lung adenocarcinoma with a micropapillary pattern (MPP) have been found to frequently invade lymphatic vessels, and the prognosis of patients with lung adenocarcinoma with an MPP is poor. In the present study, the cancer cells of lung adenocarcinomas containing an MPP were...

  • TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Lingyi Fu; Ke Shi; Jingshu Wang; Wangbing Chen; Dingbo Shi; Yun Tian; Wei Guo; Wendan Yu; Xiangsheng Xiao; Tiebang Kang; Shusen Wang; Wenlin Huang; Wuguo Deng // Molecular Cancer;2014, Vol. 13 Issue 1, p1 

    Background TFAP2B is a member of the AP2 transcription factor family, which orchestrates a variety of cell processes. However, the roles of TFAP2B in regulating carcinogensis remain largely unknown. Here, we investigated the regulatory effects of TFAP2B on lung adenocarcinomas growth and...

  • CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Monstad, Sissel E.; Drivsholm, Lars; Skeie, Geir Olve; Aarseth, Jan H.; Vedeler, Christian A. // Cancer Immunology, Immunotherapy;Feb2008, Vol. 57 Issue 2, p227 

    The collapsin response mediator protein 5 (CRMP5) antibody is usually associated with paraneoplastic neurological syndrome (PNS) and small-cell lung cancer (SCLC) or thymoma. The objective of this study was to assess the frequency of CRMP5 antibodies in patients with such tumours and to see if...

  • A global genome damage score predictive of lung cancer patients outcome. Zheng, Z.; Cantor, A.; Bepler, G. // Oncogene;8/3/2006, Vol. 25 Issue 32, p4491 

    Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected...

  • The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Al-Saad, S; Al-Shibli, K; Donnem, T; Persson, M; Bremnes, R M; Busund, L-T // British Journal of Cancer;11/4/2008, Vol. 99 Issue 9, p1476 

    Vimentin, nuclear factor-κB (NF-κB) p105, fascin, E-cadherin, TGF-β, Par6 and atypical PKC are molecular markers that play an important role in cell differentiation. Herein, we investigate their prognostic impact in primary non-small-cell carcinoma (NSCLC). Tumour tissue samples from...

  • Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. I. Abdel Salam; H. Gaballa; N. Abdel Wahab // Medical Oncology;Jun2009, Vol. 26 Issue 2, p161 

    Abstract  Lung cancer is still a leading cause of cancer related mortality all over the world with the majority of cases are discovered at a late stage. Various panels of molecular prognostic markers are being studied to map the association of these markers with response and survival. The...

  • Angiographic Findings As Prognostic Factors In Non-small-cell Lung Cancer. Abe, Katsumi; Suzuki, Kenzo; Kamata, Noriko; Yokoyama, Yoshiaki; Koike, Morio // Internet Journal of Radiology;2002, Vol. 2 Issue 2, p14 

    The aim of this study was to assess the correlation between prognosis and angiographic findings in primary non-small-cell lung cancers (NSCLCs) to determine the relationship between angiographic findings and angiogenesis. The study included 134 primary NSCLCs. Tumor vascularity, bronchopulmonary...

  • Lung cancer: radiological diagnosis and intervention.  // Thorax;Dec2003 Supplement 3, Vol. 58, piii48 

    Lung cancer is the commonest cause of cancer related death in Great Britain. Survival rates are lower than in most European countries and successful treatment depends on an early diagnosis. Researchers found that several of their lung cancer patients had unrecognized abnormalities on reviewing...

  • Retrospectively evaluate prognosis and treatment results of patients with non small cell lung cancer. Yücel, Birsen; Okur, Yıllar; Akkaş, Ebru Atasever; Eren, Mehmet Fuat // HealthMed;2012, Vol. 6 Issue 5, p1674 

    Purpose: The purpose of this study is to review the prognostic factors and treatment results of patients with non-small cell lung cancer (NSCLC) treated in our center. Methods: The data of 238 patients with NSCLC who registered at the Radiation Oncology Department of Cumhuriyet University...


Read the Article


Sign out of this library

Other Topics